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Surgical creation of jejunal self-filling blind loops (SFBL) causes small bowel bacterial overgrowth which is
associated with hepatobiliary inflammation in the susceptible Lewis and Wistar rat strains. Since hepatic injury
occurs when small bowel anaerobic bacterial concentrations are increased 4 to 6 loglo units per ml and hepatic
bacterial cultures are negative, we postulate that the inflammation is caused by absorption of phlogistic cell wall
polymers originating from bacteria within the loop. To demonstrate absorption of bacterial cell wail polymers,
we measured plasma and hepatic levels of immunoreactive peptidoglycan-polysaccharide (PG-PS) following
intraluminal injection as well as anti-PG antibodies as an indirect measure of absorption and/or accumulation
of endogenous PG. PG-PS purffied from group A streptococci was detected in plasma by enzyme-linked
immunosorbent assay after intraluminal injection; rats with SFBL showed significantly more uptake into
plasma and the liver than sham-operated rats or SFBL rats which were treated with metronidazole (P < 0.025).
Total plasma immunoglobulin A (IgA), IgG, and IgM levels did not differ among sham-operated rats and those
with self-emptying blind loops or SFBL, but plasma anti-PG IgA (P < 0.05), IgG, and IgM (P < 0.01) levels
were increased in rats with SFBL. Metronidazole and tetracycline prevented the elevation of anti-PG antibody,
but gentamicin and polymyxin B did not. Anti-lipid A, anti-soy protein, and anti-chow antibodies in plasma
were not consistently increased in rats with SFBL indicating the lack of a generalized antibody response to
luminal antigens. These data suggest that PG from normal flora bacteria is absorbed from the intestinal lumen
and that mucosal injury and/or increased luminal concentrations of PG, such as those induced by small bowel
bacterial overgrowth, lead to enhanced absorption of potentially inflammatory bacterial polymers.
Bacterial cell wall structures, such as peptidoglycan-poly-
saccharide (PG-PS) polymers, have inflammatory and immu-
nomodulating properties relevant to the pathogenesis of
chronic inflammation (28). For example, a single intraperi-
toneal injection of PG-PS derived from group A streptococci
(PG-APS) can cause chronic, spontaneously reactivating,
erosive arthritis (4) and hepatic granulomas (30) in suscepti-
ble rat strains. Purified PG-PS derived from normal enteric
floras can also induce chronic arthritis (24, 27) and granulo-
matous enterocolitis (23) in rats. We have postulated that
PG-PS from normal enteric bacteria is involved in the
pathogenesis of chronic inflammatory bowel disease and its
associated systemic complications (13, 20, 23).
In a rat model of small bowel bacterial overgrowth
(SBBO), SBBO develops within 1 week after surgical cre-
ation of the self-filling blind loop (SFBL) and causes intes-
tinal mucosal injury, as indicated by the presence of disac-
charidase deficiency (9, 25, 26), protein-losing enteropathy
(10), and abnormalities of sodium and glucose transport (9,
25). Recently, we showed that susceptible rat strains de-
velop hepatobiliary injury following the experimental induc-
tion of SBBO (12a, 13). Hepatic inflammation was charac-
terized by portal-tract expansion with acute and chronic
inflammatory cell infiltration and by areas of parenchymal
inflammation with occasional necrosis, while biliary abnor-
malities consisted of bile duct proliferation, tortuosity of
intrahepatic ducts, and dilatation of the extrahepatic ducts.
Hepatic injury was not due to septicemia, peritonitis, bacte-
rial infection of the liver, or nutritional deprivation (13).
Hepatobiliary inflammation was, however, related to in-
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creased concentrations of anaerobic bacteria within the blind
loop, since rats with self-emptying blind loops (SEBL),
which have anaerobic bacterial concentrations 2 to 3 log1o
units per ml lower than rats with SFBL, did not develop
hepatic injury (13) and metronidazole prevented the lesions
(14). SBBO may cause increased absorption of PG-PS be-
cause of increased luminal concentrations of bacterial cell
wall polymers as well as enhanced mucosal permeability.
Our hypothesis is that absorbed bacterial cell wall polymers
play a role in the development of hepatic injury associated
with SBBO (13). In this paper, we present evidence indicat-
ing that immunoreactive PG-PS can be absorbed from the
intestine, on the basis of experiments in which plasma and
hepatic PG-PS concentrations are measured following direct
injection into the blind loop and on the basis of data showing
an increase in plasma and luminal antibody response to
endogenous PG after the creation of experimental SBBO.
This work was presented in part at the 11th International
Convocation on Immunology, Buffalo, N.Y., June 1988, and
at the annual meeting of the American Gastroenterological
Association, New Orleans, La., May 1988.
MATERIALS AND METHODS
Animals. Inbred Lewis rats and outbred Wistar rats were
used. Lewis rats were studied at 4 weeks postoperatively
and Wistar rats were studied at 12 weeks postoperatively on
the basis of the time course for the development of hepatic
injury in these strains following the creation of SFBL (13).
Initial body weights were 175 to 200 g, and weekly weights
were recorded.
Surgical procedures. According to the method of Cameron
et al. (3), 10 cm ofjejunal SFBL was surgically created 7 cm
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distal to the ligament of Treitz by using a sterile technique
and ether anesthesia. This method caused SBBO within 1
week following surgery (26). Control groups consisted of
sham-operated animals which had laparotomies but no intes-
tinal anastomoses and which did not develop SBBO, as well
as rats which had SEBL in which the loops are constructed
in an isoperistaltic fashion so that they continuously empty
(13). Although SEBL have an increase in anaerobic bacteria
of 1 to 2 log1o units per ml over baseline jejunal bacterial
concentrations, manifestations of SBBO do not develop.
Experimental design. Heparinized plasma was collected
from the tail vein immediately prior to surgery and then 2
weeks after surgery for Lewis rats and 2 and 6 weeks after
surgery for Wistar rats. After the rats were killed by cervical
dislocation, blood, peritoneums, abdominal organs, and in-
testinal loop contents were anaerobically cultured as de-
scribed below, and intestinal mucosas from the loops were
harvested for disaccharidase analysis. Luminal contents of
the ceca and blind loops or the corresponding 10-cm seg-
ments ofjejunum of sham-operated rats were flushed with 10
ml of iced saline and stored for immunoglobulin determina-
tions at -20°C in the presence of aprotinin, phenylmethyl-
sulfonyl fluoride, and azide as previously described (15).
Intestinal segments were fixed in 10% buffered Formalin and
then processed for histology and stained by using hematox-
ylin and eosin and periodic acid-Schiff stain diastase diges-
tion techniques.
Antibiotic treatment. Within 24 h of surgery, rats were
allowed to drink ad libitum. The daily fluid volume con-
sumed was recorded, and antibiotic was added so that the
appropriate dose was ingested. Since each rat consumed 25
to 30 ml of water daily, oral antibiotics were added to a 50-ml
volume such that the total daily dose required was contained
in 25 ml. The fluid volumes consumed by the rats did not
change after addition of antibiotics. The excess solution was
discarded daily. Oral doses of antibiotics were administered
as follows (in milligrams per kilogram of body weight per
day): gentamicin, 30; polymyxin B, 9; metronidazole, 50;
and tetracycline, 20. While testing intraperitoneal injections
of polymyxin B, we observed 50% mortality within 1 to 2 h
due to respiratory arrest with doses recommended by Nolan
and Leibowitz (19) and Gut et al. (8). A nonlethal dose of 0.5
mg/kg/day given intraperitoneally was determined by titra-
tion.
Measurement of total IgA, IgG, and IgM. Antibodies were
measured by enzyme-linked immunosorbent assay (ELISA),
using a sandwich technique as described previously (15). All
dilutions were in phosphate-buffered saline (PBS), pH 7.4,
such that 100 ,ul was applied to each well. Microtiter plates
(Dynatech, McLean, Va.) were washed three times with
PBS-Tween (0.5%) between each incubation step. Microtiter
wells were coated with 500 ng of affinity-purified anti-rat
immunoglobulin A (IgA), IgG, or IgM antibody for 15 h at
4°C. After unbound sites were blocked with 0.5% bovine
serum albumin, samples or immunoglobulin standards were
incubated for 8 h at 25°C. Subsequently, affinity-purified
anti-rat IgA, IgG, or IgM antibody which was conjugated to
alkaline phosphatase (AP) was applied for 15 h at 4°C. Color
developed in the presence of a para-nitrophenyl substrate
(Sigma tablets [5 mg/ml]; Sigma Chemical Co., St. Louis,
Mo.), and the results were read with an ELISA reader at an
optical density of 410 nm after 30 min. An IgA standard was
prepared from purified rat bile (15). Anti-rat IgA was affinity
purified from goat anti-rat secretory IgA (ICN Immunobio-
logicals, Lisle, Ill.) by using affinity chromatography with
purified rat biliary IgA bound to Reactigel (Pierce Chemical
Co., Rockford, Ill.) and conjugated with AP as described
previously (15). The following were purchased: rat IgM
standard (Calbiochem, La Jolla, Calif.); affinity-purified rab-
bit anti-rat IgG-AP (Sigma Chemical Co.) and rat IgG
standard, affinity-purified rabbit anti-rat IgG, rabbit anti-rat
IgM, and rabbit anti-rat IgM-AP (Cappel, Organon Teknika,
West Chester, Pa.). Standard curves were linear in the
following ranges: IgA, 0 to 100 ng/ml; IgG, 0 to 200 ng/ml;
and IgM, 0 to 5 ,ug/ml. The coefficient of variance was less
than 10% for each assay.
Antigens used in the ELISA. PG for the initial coating of
the solid-phase ELISA plate was purified from Streptococ-
cus pyogenes D58 as previously described (6). Briefly,
bacteria were fragmented in a Braun shaker, cell walls were
recovered by sodium dodecyl sulfate treatment, and then PG
was extracted with hot formamide. Lipid A was purchased
from Ribi Immunologic and Chemical Research (Hamilton,
Mont.). Soy protein was a generous gift from Wesley Burke,
University of Arkansas at Little Rock. A mixed "chow
antigen" was made by dissolving 30 g of rat chow (Agway
Inc., Syracuse, N.Y.) in 100 ml of water and then homoge-
nizing and centrifuging the solution so that the supernatant
was decanted with a final protein concentration of 5 mg/ml.
Measurement of antibody. In the first step of the ELISA
for anti-PG antibody, microtiter wells were coated with PG
(2 ,ug/ml diluted in PBS) and incubated for 15 h at 4°C. The
remaining steps were identical to those described above,
with the same affinity-purified anti-rat IgA, IgG, and IgM-AP
conjugates used. The standard curves for each immunoglob-
ulin were in a lower range because the amount of specific
antibody is less than the total immunoglobulin (IgA, 0 to 15
ng/ml; IgG, 0 to 25 ng/ml; and IgM, 0 to 500 ng/ml). The time
for color reaction of these assays was 90 min. Preincubation
of plasma with 10 to 50 ng of PG per ml resulted in
appropriately lower measurements of specific antibodies of
all three immunoglobulin subclasses. For lipid A, soy protein
and mixed chow antigen (2 ,ug/ml in PBS) were used as the
initial coat on the Dynatech microtiter plates.
Bacterial cultures of organ specimens. A modification of the
technique of Berg was used (1). The abdomen was shaved
and then washed with Pharmadine (Sherwood Pharmaceuti-
cals, Mahwah, N.J.). The skin was opened with one set of
sterile instruments, and then the muscle and peritoneum
were opened with a second set of sterile instruments. Peri-
toneal cultures were performed by swabbing the viscera with
a sterile cotton-tipped applicator stick. Specimens of the
liver, spleen, and mesenteric lymph node (MLN) were
excised with a separate set of sterile instruments, weighed in
sterile Kimax brand Ten Broeck tissue grinders (American
Scientific Products, McGraw Park, (Ill.), and homogenized
by using 0.2 g of tissue per ml of brain heart infusion (BHI)
(Scott Laboratories, Inc., Fiskeville, R.I.) for MLN speci-
mens and 1.0 g of tissue per ml of BHI for liver and spleen
specimens. Cardiac blood was aspirated in a sterile fashion.
All specimens were inoculated on prereduced BHI agar
plates which were cultured anaerobically in BBL GasPak
jars (Becton Dickinson, Cockeysville, Md.) at 37°C for at
least 72 h.
Bacterial cultures of intestinal contents. Aliquots of intes-
tinal fluid for antibody determination were collected prior to
the addition of inhibitors, homogenized, diluted serially in
BHI from 10-1 to 1010, and cultured anaerobically to
determine bacterial concentrations of the loop or jejunum.
Measurement of disaccharidases. Intestinal mucosa was
removed by being scraped with a glass slide while on ice,
weighed, and homogenized in 5 mM EDTA with a Waring
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blender. The homogenate was stored at -20°C in the pres-
ence of azide (0.02%), aprotinin (500 kIU/ml), and phenyl-
methylsulfonyl fluoride (0.5 mM). Mucosal disaccharidases
(lactase and sucrase) were determined by the method of
Dahlqvist (5).
Measurement of proteins. Plasma and mucosal proteins
were measured by the method of Lowry et al. (16).
Intraluminal injection of PG-PS. In order to show that
PG-PS could be absorbed from the intestinal lumen, Lewis
rats were injected intraluminally with PG-PS (15 ,ug of
rhamnose per g of body weight) 4 weeks following SFBL
surgery. Sham-operated and metronidazole-treated SFBL
groups of rats were also used. PG-PS polymers were purified
from S. pyogenes D58 (group A) and sonicated as previously
described to yield fragments ranging from 5 x 106 to 5 x 108
Da (22, 23, 27). At 4 weeks, rats underwent laparotomies,
and the blind loops or corresponding sham-operated jejunal
segments were injected via a 24-gauge catheter (Jelko IV
Catheter; Critikon Inc., Tampa, Fla.) and then flushed with
1 ml of normal saline to prevent peritoneal soiling. The
catheter was removed immediately after injection. Tail vein
plasma was obtained prior to injection and 2, 7, 10, 16, 19,
22, 25, 28, 31, and 42 h later. At the 42-h sampling, when the
rats were killed, portal-vein blood was obtained in addition
to tail vein blood.
Measurement of PG-APS in plasma and liver homogenates.
By using an affinity-purified antibody to group A streptococ-
cal polysaccharide, PG-APS was measured by an ELISA
technique as previously described (22). Liver tissue was
homogenized in a Tris buffer with 1% Tween 20, pH 7.4, in
a ratio of 4 ml of buffer to 1 g of tissue.
Statistical analysis. Antibody and disaccharidase levels for
the experimental groups were compared by using the two-
tailed Student's t test. The incidences of positive bacterial
cultures of MLNs were compared by using the chi-square
method.
RESULTS
Luminal bacterial counts. There was an increase in anaer-
obic bacteria of 0.7 to 1.7 log1o units per ml in rats with
SEBL compared with the amount in sham-operated rats, but
rats with SFBL had an increase in luminal anaerobic bacteria
of 3.5 to 3.6 log1o units per ml compared with the number in
rats with SEBL (Table 1). There was no significant differ-
ence between the totals of anaerobic bacteria in SFBL rats
of the Lewis and Wistar strains.
Measurement of systemic absorption of PG-PS injected into
the intestinal lumen. We first sought to determine whether
immunoreactive PG-PS injected into the proximal small
bowel would be systemically absorbed. Following injection
of purified PG-APS into the SFBL or comparative sham-
operated jejunal segment, blood samples were collected and
tested by ELISA for PG-APS immunoreactivity. The time
course is shown in Fig. 1, which presents the mean plasma
value at each time point for the three rat groups. The areas
under the curves represent total plasma uptakes, which are
compared in Table 2 for sham-operated rats, SFBL rats
without antibiotic treatment, and SFBL rats with metronida-
zole treatment. All rats had PG-APS present in plasma,
generally peaking 7 to 10 h after injection. The area under the
curve was significantly greater for untreated rats with SFBL
than for those treated with metronidazole (P < 0.025) or
sham-operated rats (P < 0.020). The area under the curve for
the metronidazole-treated rats with SFBL was not signifi-
cantly different from that for sham-operated rats. For all
TABLE 1. Weight gain and bacterial counts in rats with
and without blind loops
No. of rats with
Experimental Wt gain Log10 culture-positive
group' n (in g)b (CFU/Ml)b MLNs/no.
(CFU/ml)b ~tested
Lewis
SHAM 8 41 10 3.9 ± 0.6 1/5
SEBL 5 36 ± 18 5.6 ± 0.4d 2/5
SFBL 8 10 ± i5e 9.1 ± 0o5d 6/7
SFBL Gent 10 24 ± 15e 8.5 ± 0.5d 6/10
SFBL Poly 10 -20 + 19d 9.2 ± 0 9d 10/10
SFBL Met 7 44 ± 25 8.3 ± 0.4d 5/6
SFBL Tetra 7 30 ± 12 9.1 ± 0.2d 5/7
Wistar
SHAM 10 324 ± 28 4.9 ± 0.6 2/6
SEBL 4 271 ± 42d 5.6 ± 1.2 0/3
SFBL 11 209 ± 74d 9.2 ± 0.7d 6/7
SFBL Met 7 239 ± 69d 8.3 + o.gd 5/6
" SHAM, Sham operated; Gent, treated with gentamicin; Poly, treated with
polymyxin B (pooled group treated with either oral or intraperitoneal injec-
tions); Met, metronidazole; Tetra, tetracycline. Lewis rats and Wistar rats
were tested at 4 and 12 weeks after surgery, respectively.
b All values are mean ± SD.
c Number of rats with MLNs which grew bacteria when cultured.
d P < 0.001 versus sham-operated rats.
e P < 0.05 versus sham-operated rats.
groups of rats, values for portal-venous blood drawn at 42 h
were each higher than the values for tail vein blood drawn
simultaneously, indicating absorption of PG-APS by the
intestine, with subsequent hepatic extraction and/or dilution
by systemic blood. Finally, liver PG-APS accumulation 42 h
after luminal injection was markedly increased in SFBL rats
which received no antibiotic therapy compared with that in
SFBL rats treated with metronidazole and sham-operated
rats. Levels of PG-APS in liver homogenates from metron-
idazole-treated rats with SFBL were no different from levels
for sham-operated rats. Plasma and liver homogenates from
10 Lewis SFBL rats which were not injected with PG-APS
were tested by the ELISA. The plasma samples ranged from
0 to 0.5 ng/ml, and the liver homogenates ranged from 0.5 to
2.0 ng/g of liver. These values are slightly higher than the
background of buffer in the ELISA and approximately 10
times lower than the lowest values obtained for rats injected
with PG-APS.
Antibody responses to endogenous PG-PS. To determine
whether an immune response to proliferation of bacteria
within the SFBL developed, we measured plasma and lumi-
nal anti-PG antibodies.
Total immunoglobulin levels in plasma. Plasma immuno-
globulin levels in Lewis and Wistar rats showed no change in
total IgG or IgM at 4 and 12 weeks, respectively, after the
creation of SFBL, SEBL or sham operation. Wistar and
Lewis rats with SFBL had mildly increased plasma IgA
levels, 17 and 61%, respectively, compared with levels for
non-SFBL rats (P < 0.05). Antibiotic treatment did not alter
total antibody concentrations.
Plasma levels of antibodies to PG and luminal antigens.
Compared with sham-operated rats, Lewis rats with SFBL
for 4 weeks and Wistar rats with SFBL for 12 weeks
developed significant increases in specific anti-PG antibody
for all three immunoglobulin classes in plasma (Table 3)
despite the fact that total immunoglobulin levels were not
different among the groups. The increased anti-PG antibody
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FIG. 1. Plasma PG-APS levels following intraluminal injection of PG-APS. The curves represent the mean ± standard error for plasma
PG-APS for the three rat groups at each time point. PG-APS (15 ,g/g of body weight) was injected intraluminally into the SFBL or the
corresponding jejunal segments of sham-operated Lewis rats 4 weeks after surgery. Plasma PG-APS was measured by ELISA with affinity-
purified antibodies to group A streptococcal polysaccharide. SFBL-MET, Rats which had SFBL and which were treated with metronidazole.
levels could not be attributed to surgical manipulation of the
intestine, since rats with SEBL did not have elevated levels
compared with those of sham-operated rats. The rise in
anti-PG antibodies was not altered in rats treated with
gentamicin (except for anti-PG IgA) or polymyxin B but was
prevented by metronidazole and tetracycline. Rats which
had SFBL and which were treated with metronidazole and
tetracycline had significantly lower anti-PG antibody levels
than SFBL rats which received no antibiotic treatment.
There was a small but statistically significant rise in anti-PG
IgG and anti-PG IgM levels in Lewis rats and in anti-PG IgM
in Wistar rats with sham operations at 4 and 12 weeks,
respectively, following surgery. However, the elevated an-
ti-PG IgG and anti-PG IgM levels in SFBL rats which had no
antibiotic treatment, which received gentamicin, or which
received polymyxin B treatment were significantly greater
than the naturally elevated levels found in the sham-operated
rats (Fig. 2 and Table 3).
The rise in anti-PG IgA found in Lewis and Wistar rats
with SFBL was not explained solely by the increase in total
IgA. The percentage of total plasma IgA which was specific
anti-PG IgA increased from 0.16 to 0.72% (450% increase) in
TABLE 2. PG-APS absorption following intraluminal injectiona
Amt of PG-APS in specimen from:
Experimental Area
groupb (cm2)c Liver Portal vein Tail vein
(ng/g) (ng/ml) (ng/ml)
SHAM 5.5 ± 4.7 30 ± 19 7.0 ± 12 0.5 ± 1.2
SFBL Met 8.5 ±6.7 46 ± 7 5.6 ± 5.0 1.3 ± 2.3
SFBL 62.0 ± 24 0d 262 ± 45e 12.7 ± 7.0 1.0 ± 1.7
a All values are mean + SD.
b For each group, n = 3. SHAM, Sham-operated rats; Met, metronizadole.
cArea refers to the area under the curve shown in Fig. 1. The area reflects
total PG-APS plasma uptake over 42 h.
d p < 0.025 for SFBL rats which received no antibiotic treatment compared
with metronidazole-treated SFBL and sham-operated rats.
Pp < 0.001 for SFBL rats which received no antibiotic treatment compared
with metronidazole-treated SFBL and sham-operated rats.
Lewis rats and from 0.18 to 0.83% (450% increase) in Wistar
rats, compared with only a 61% increase in total IgA in
Wistar rats and a 17% rise in total IgA in Lewis rats.
For Lewis and Wistar SFBL rats with no antibiotic
treatment, plasma anti-PG antibody levels showed an in-
crease with time (Fig. 2). The levels were significantly
greater than preoperation levels at 4 weeks in Lewis rats and
at 6 and 12 weeks in Wistar rats.
Using similar ELISA techniques on the same blood sam-
ples as those tested for anti-PG antibody, we were unable to
show consistent elevations of specific anti-lipid A, anti-soy
protein, or anti-whole chow antibodies in the same groups of
Lewis rats for which data are shown in Table 3 (data not
shown). Sporadic increases in antibodies occurred; for ex-
ample, anti-soy IgM levels increased 50%, anti-chow IgM
levels increased 30% in rats with SFBL, and anti-lipid A IgG
levels increased 20% in rats treated with tetracycline (for all,
P < 0.05), but these elevations are of lower magnitude than
and are not as consistent as the elevations of anti-PG
antibodies shown in Table 3. These sporadic increases
represent only 3 elevations of 45 data (3 antigens, 3 immu-
noglobulins, and 5 groups of Lewis rats [with no antibiotic
treatment or with gentamicin, polymyxin B, metronidazole,
or tetracycline treatment]).
Intestinal IgA levels. Wistar rats had more total IgA within
the blind loop than did Lewis rats (Table 4) because their
loops were larger because of greater body weight. Control
10-cm jejunal segments from sham-operated rats or SEBL
rats had significantly lower concentrations of luminal IgA
than did blind loops, by a factor of approximately 30, as
previously reported (18). Because of the large difference in
IgA in jejunal segments of SFBL rats and sham-operated or
SEBL rats, we also studied IgA from the ceca and discov-
ered that total cecal IgA in Wistar and Lewis rats was not
significantly different among rats with SFBL, SEBL, or
sham operations (Table 4). The blind loops contained more
total IgA than ceca, but this difference was also due to larger
volumes, since the concentrations (approximately 300 ,ug/
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TABLE 3. Plasma anti-PG antibody in rats with and without blind loops
Experimental ng of antibody/ml (mean + SD)Exprimental ngroups' IgA IgG IgM
Lewis
Preop 18 311 ± 51 1,348 ± 651b 1,119 ± 540b
Postop
SHAM 5 310 ± 48 2,461 + 978 1,586 ± 255
SEBL 5 414 ± 80 3,842 ± 2,605 1,876 ± 351
SFBL 8 1,915 ± 819c 4,137 ± 1,836b 2,491 ± 789
SFBL Gent 10 382 ± 64 3,508 ± 824b 2,879 ± 966b
SFBL Poly, P.O. 6 747 ± 214c 4,869 ± 2,052b 3,967 ± 1,390c
SFBL Poly, I.P. 4 1,186 ± 324c 4,472 ± 1,651b 4,121 ± 1,575d
SFBL Met 7 302 ± 49e 2,574 ± 432f 1,237 ± 367k
SFBL Tetra 7 316 ± 106e 2,649 ± 570 1,361 ± 341f
Wistar
Preop 10 420 ± 350 1,282 ± 809C 837 ± 441
Postop
SHAM 9 480 ± 410 3,251 ± 1,571 1,070 ± 373
SEBL 4 371 ± 107 1,478 ± 665d 781 ± 412
SFBL 9 2,690 ± 2,020d 10,306 ± 4,730d 5,115 ± 826C
SFBL Met 7 295 ± 25f 2,398 ± 1,488e 967 ± 215e
a Lewis rats and Wistar rats were tested at 4 and 12 weeks after surgery, respectively. Preop, Blood drawn before surgery; Postop, blood drawn at the end of
the experiment; p.o., per os; i.p., intraperitoneally. For other abbreviations, see Table 1, footnote a.
b p < 0.05 compared with sham-operated rats.
c P < 0.005 compared with sham-operated rats.
d p < 0.01 compared with sham-operated rats.
e p < 0.001 compared with SFBL rats which received no antibiotic treatment.
f P < 0.05 compared with SFBL rats which received no antibiotic treatment.
ml) were not significantly different among the experimental
groups.
Intestinal anti-PG IgA levels. Total specific anti-PG anti-
body levels in loops of Lewis and Wistar rats with SFBL
(378 and 1,172 ng, respectively) were significantly higher
than in control 10-cm jejunal segments which contained 8
and 5 ng, respectively, of specific antibody (Table 4). SFBL
Lewis and Wistar rats which were treated with metronida-
zole had significantly lower intestinal anti-PG IgA levels than
those which received no antibiotics (P < 0.005 and P < 0.05,
respectively).
Lewis rats with SFBL for 4 weeks and Wistar rats with
SFBL for 12 weeks also had significantly increased specific
cecal anti-PG antibody levels compared with those of sham-
operated and SEBL groups (Table 4), by approximately
twofold. This increase in specific cecal anti-PG antibodies
was prevented by metronidazole treatment. Total specific
cecal antibody levels in the sham-operated and SEBL groups
were not different for the two strains.
Evidence of intestinal injury. To demonstrate the presence
of intestinal mucosal injury, which could permit enhanced
luminal PG absorption (20), we compared jejunal lactase and
sucrase in rats with and without blind loops (data not
shown). Following construction of SFBL, both Lewis and
Wistar rats showed a significant decrease (approximately
50%) in disaccharidase levels. Metronidazole and tetracy-
cline each prevented disaccharidase deficiency in SFBL
rats, but gentamicin and polymyxin B did not. Rats which
had SFBL and which were treated with metronidazole and
tetracycline had higher disaccharidase levels than SFBL rats
which were not treated with antibiotics (significance, P <
0.05 [except for lactase levels in Lewis rats treated with
metronidazole]).
We compared the histologies of intestinal blind loop
mucosas from nine Lewis rats and nine Wistar rats. Under
light microscopy, all specimens demonstrated the findings
typical ofSBBO reported elsewhere (18, 29), including intact
epithelial layers with no ulcerations. There was marked
hypertrophy of the muscle layers. All specimens had an
increased number of lymphocytes within the lamina propria,
and some specimens had polymorphonuclear leukocytes.
There were no consistent histologic differences between the
rat strains.
Relationship of MLN culture to antibody response. In this
study, none of the rats with SFBL had infection of the blood,
peritoneum, liver, or spleen to account for the elevated
plasma antibody levels. However, 86% (12 of 14) of SFBL
rats given no antibiotic treatment had positive cultures of the
MLN, compared with only 26% (5 of 19) of sham-operated
and SEBL rats (chi-square = 11.45; P < 0.01) (Table 1).
Positive MLN cultures occurred in 80% (31 of 39) of SFBL
rats which received antibiotic treatment. Even tetracycline
and metronidazole failed to prevent positive MLN cultures,
since 79% (15 of 19) were positive. These frequencies of
positive MLN cultures were not statistically different from
those for SFBL rats which received no antibiotic treatment.
To determine whether positive MLN cultures would cause
elevated plasma anti-PG antibody levels, these variables
were correlated. For the 33 rats with no antibiotic therapy
(14 SFBL, 8 SEBL, and 11 sham operated), there was no
correlation of a positive or negative MLN culture with
antibody levels. Since each rat had plasma anti-PG IgA, IgG,
and IgM levels, there were 99 possible matched pairs (i.e.,
positive cultures with elevated antibody levels or negative
cultures with no change in antibody level). Of the 99 total
possible matched pairs, only 52 actually matched (47 did not
match), with no difference noted between rat strains or
among antibody classes. Therefore, increased plasma anti-
body levels were not explained by translocation of viable
organisms from the intestinal lumen to the MLN.
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FIG. 2. Plasma anti-PG antibody levels in Lewis and Wistar rats
with and without blind loops. All values are the mean + standard
deviation (SD) for at least eight rats per group. Plasma antibody
levels were determined from tail vein blood prior to surgery and then
at 2, 6, and 12 weeks for Wistar rats with blind loops and at 2 and 4
weeks for Lewis rats with blind loops. Pre-op, Antibody levels
obtained prior to surgery. These values represent pooled data from
sham-operated rats and those with SFBL. Symbols: *, rats with
SFBL; O, sham-operated rats at the end of the experiment; *, **,
and ***, P < 0.05, 0.005, and 0.001, respectively, compared with
preoperation levels.
DISCUSSION
This study demonstrates that PG-APS injected into SFBL
rats is absorbed more than that injected into sham-operated
rats or rats which had blind loops and which were treated
with metronidazole. Therefore, SBBO is associated with
increased PG-APS absorption. The data derived from the
area under the curve (Fig. 1) showed that rats which had
SFBL and which were treated with metronidazole had
PG-APS absorption similar to that of sham-operated rats and
that both had approximately eightfold less absorption than
that which occurred in SFBL rats with no antibiotic treat-
ment. PG-APS is absorbed from the intestine and probably
delivered to the liver via the portal vein, since the PG-APS
level was higher in portal-venous blood than in tail vein
blood in every rat examined.
As well, SBBO is associated with an elevated specific
antibody response to endogenous bacterial cell-wall polymer
PG in Lewis and Wistar rats, and metronidazole and tetra-
cycline prevent this response. The antibody response was
not due to infection in the blood, peritoneum, liver, or
TABLE 4. Enteral IgA in rats with and without blind loops
Specimen source . %




SEBL/SHAM 7 106 ± 54e 8 + 3e 7.5
SFBL 8 4,800 ± 2,080 378 ± 153 7.9
SFBL Gent 6 4,652 ± 1,890 427 ± 125 9.2
SFBL Poly 6 4,320 + 899 428 ± 103 9.9
SFBL Met 7 4,917 ± 1,121 112 ± 92e 2.3
Wistar
SEBL/SHAM 7 114 ± 79e 5 ± 4e 4.4
SFBL 5 7,740 ± 2,290f 1,172 ± 878 15.1
SFBL Met 5 6,594 ± 1,875 183 ± 1639 2.8
Cecum
Lewis
SEBL/SHAM 5 3,030 ± 1,880 112 ± 59h 3.7
SFBL 10 3,530 ± 1,020 231 ± 71 6.5
SFBL Met 5 3,240 ± 865 125 ± 49h 3.9
Wistar
SEBL/SHAM 7 3,550 ± 1,310 116 ± 72h 3.3
SFBL 6 3,310 ± 1,420 258 ± 122 7.8
SFBL Met 5 3,122 ± 1,115 110 ± 86h 3.5
Lewis rats and Wistar rats were tested 4 and 12 weeks, respectively, after
surgery. SEBL/SHAM, Pooled data for controls. For other abbreviations, see
Table 1, footnote a.
b Total IgA per segment of bowel, which means the entire contents of the
loop of SEBL and SFBL rats and the volume flushed through 10 cm of
proximal jejunum for sham-operated rats. All values are mean ± SD.
All values are mean ± SD.
d (Specific IgA/total IgA) x 100.
P < 0.001 compared with SFBL rats which received no antibiotic
treatment.
f P < 0.05 for Wistar rats compared with Lewis rats.
g P < 0.005 compared with SFBL rats which received no antibiotic
treatment.
h P < 0.05 compared with cecal IgA from SFBL rats which received no
antibiotic treatment.
spleen, and the response did not correlate with the translo-
cation of viable organisms to MLNs. This antibody response
demonstrates the immunogenic potential of luminal normal
flora bacterial cell wall polymers. The origin of specific
anti-PG antibody cannot be determined from these data, but
the antibody may arise from the gut-associated lymphoid
tissue or from systemic sources, such as the spleen or
marrow. The rise in anti-PG antibody required 6 to 12 weeks
for Wistar rats, which is long after disaccharidase deficiency
and protein-losing enteropathy have been established, per-
haps indicating that the accumulation of the antigen as well
as its absorption is important in induction of an antibody
response.
Anti-lipid A, anti-soy protein, and anti-whole chow anti-
bodies were only minimally and inconsistently increased in
rats with SFBL, indicating that anti-PG antibody is not
simply part of a generally increased response to luminal
antigens accompanying SBBO and/or mucosal injury. The
fact that anti-lipid A antibody levels were not elevated in rats
with SFBL could indicate that lipopolysaccharide (LPS) is a
weak immunogen compared with PG, that there is not much
LPS absorbed in rats with SBBO, or that endogenous LPS in
control rats has already stimulated a maximal immune re-
sponse. Previously, we showed that there were increased
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coli, Bacteroides vulgatus, and mixed anaerobic flora from
blind loops, but the antigenic sites on these sonicates were
unknown (15).
Plasma anti-PG IgG and IgM increased naturally over time
in sham-operated rats, since postoperation levels were sig-
nificantly greater than preoperation levels. The development
of natural antibodies to this ubiquitous bacterial antigen with
increased lengths of exposure to intestinal PG-PS and mat-
uration of the immune system suggests continuous, low-
grade absorption of luminal PG-PS. Antibody responses to
other bacterial antigens increase with age (2, 17). We have
previously demonstrated that serum anti-PG antibody levels
increased following feeding of PG-APS to mature rats (21)
and that colonic PG-APS absorption is enhanced by acetic
acid-induced mucosal injury (22). Serum anti-PG antibody
levels are increased in Crohn's disease; are especially asso-
ciated with extraintestinal manifestations, juvenile rheuma-
toid arthritis, and ankylosing spondylitis; and are possibly
increased in patients who have undergone a jejunoileal
bypass for morbid obesity who develop arthritis (7). These
data support the hypothesis that absorption of toxic PG-PS
from enteric bacteria occurs normally in small amounts but
that it may have pathogenic significance in several idio-
pathic, chronic inflammatory conditions (20).
Since IgA levels in blind loops were approximately 30-fold
higher than levels in SEBL and sham-operated jejunum
segments, measurement of cecal IgA was a useful parameter
because the ceca of the rats in the three groups were
approximately the same size and contained similar amounts
of total IgA. Cecal IgA may represent the passive accumu-
lation of antibody from proximal mucosa and bile, but
increased ratios of anti-PG IgA to total IgA in the ceca of rats
with experimental SBBO may also indicate that the entire
intestine has been sensitized to PG by jejunal bacterial
overgrowth. Interestingly, treatment with metronidazole
prevented increased anti-PG IgA concentrations within both
the SFBL and the ceca.
Although SBBO may induce a polyclonal IgA response, an
alternate explanation for elevated levels of total IgA in
plasma in Lewis and Wistar rats is the hepatic injury induced
by SBBO (13), since hepatic injury has been shown to result
in higher plasma IgA levels in humans (11) and rats (12)
because of decreased biliary secretion of secretory IgA and
IgA-antigen complexes. However, the increase in anti-PG
IgA was 450%, compared with only a 61% increase in total
IgA in Wistar rats and a 17% increase in total IgA in Lewis
rats. The anti-PG IgA level was also higher than the specific
antibody response to lipid A and the dietary soy and chow
antigens, thereby indicating an increased specific IgA im-
mune response against PG rather than a nonspecific defect in
biliary excretion of secretory IgA or a nonspecific polyclonal
IgA response.
The ELISA for measuring PG-APS is very specific for the
polysaccharide of group A streptococci and has minimal
cross-reactivity with cell wall polymers derived from other
bacteria. This fact was reported by Eisenberg et al. (6) with
regard to the radioimmunoassay for PG-APS, which was the
forerunner to our ELISA and utilizes the same antibody. We
confirmed this by measuring PG-APS in plasma and liver
homogenates from SFBL Lewis rats which were not injected
with PG-APS and found these levels to be approximately 10
times lower than the lowest values obtained following PG-
APS injection. The anti-PG assay, however, is not specific
and should identify antibodies to PG from many bacterial
sources, since two of three documented epitopes are found
in almost all bacterial species. Streptococci were used as a
source of PG that will cross-react with most bacterial spe-
cies. We do not suggest that anti-PG antibodies arise from
enteric streptococci but instead that anti-PG antibody re-
flects a response to luminal PG from a wide variety of
bacterial species.
The elevated levels of plasma antibody are an indirect
measure of increased absorption of PG. The increased ratio
of anti-PG IgA to total IgA in plasma (450%) compared with
the luminal ratio (200%) indicates that there is at least an
element of systemic anti-PG antibody production. These
data, in conjunction with direct measurement of transport of
intraluminally injected PG-APS from the SFBL, support our
hypothesis (13) that bacterial cell wall PG polymers derived
from normal flora bacteria are absorbed from the intestinal
tract in small amounts in the normal state, with enhanced
transport under conditions which perturb gut permeability or
increase luminal concentrations of PG-PS. Metronidazole
and tetracycline decreased total luminal bacterial numbers
only minimally but prevented disaccharidase deficiency.
Recently, we showed that metronidazole and tetracycline
treatment eliminated certain bacterial species which may
have been responsible for mucosal injury (14). This confirms
the data of Welkos et al. (31), who showed that metronida-
zole caused small changes in the numbers of anaerobic
bacteria within blind loops but eliminated Bacteroides spp.
Therefore, metronidazole and tetracycline may have pre-
vented the development of elevated anti-PG antibody levels
by decreasing intestinal injury typically induced by SBBO.
Gentamicin and polymyxin B did not reverse mucosal injury
(as demonstrated by low disaccharidase levels), did not
eliminate Bacteroides spp. (14), and did not prevent elevated
anti-PG antibody levels.
The creation of blind jejunal loops and the consequent
large overgrowth of anaerobic bacteria both increases the
luminal PG-PS concentration and induces mucosal injury.
Enhanced absorption of these toxic endogenous bacterial
cell wall polymers from the lumen may lead to hepatobiliary
injury associated with intestinal bacterial overgrowth in
susceptible rat strains (13) and may have implications for the
pathogenesis of extraintestinal manifestations of human in-
flammatory bowel disease and jejunoileal bypass.
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